Abstract
Background Anhedonia is a core symptom of major depressive disorder (MDD). While its narrow definition as a hedonic or consummatory deficit evolved to encompass anticipatory and motivational reward facets, it remains unclear where reward deficits manifest. As evidence accumulates for metabolic hormones affecting reward processing, studying their role in mitigating reward deficits could yield crucial insights. Here, we compare food reward ratings between patients with MDD and healthy control participants (HCPs) from anticipation to consummation and evaluate associations with anhedonia and metabolic parameters.
Methods We conducted a cross-sectional study with 103 participants, including 52 patients with MDD and 51 HCPs. After overnight fasting, blood samples were collected to determine levels of ghrelin, glucose, insulin, and triglycerides. Participants completed a taste test, providing repeated ratings of wanting and liking, gradually moving from reward anticipation to consummation.
Findings Patients with MDD showed decreased wanting (p = .046) but not liking for food rewards during visual anticipation. However, once food was inspected and tasted, patients increased wanting relative to HCPs (p = .004), providing strong evidence against a consummatory deficit (Bayes Factors > 9). In contrast to a narrow definition of anhedonia, higher scores on the Snaith-Hamilton Pleasure Scale were associated with reduced anticipatory food wanting (p = .010) and more pronounced increases in wanting with reward proximity (p = .037). Acyl ghrelin was associated with higher food reward ratings, while poor glycemic control was linked to symptoms of anhedonia.
Interpretation Our study demonstrates that MDD and anhedonia are associated with reduced anticipation of rewards rather than consummatory pleasure deficits. Notably, ghrelin’s association with elevated reward ratings implicates the gut-brain axis as a potential target for treating reward deficits in MDD.
Funding DFG KR 4555/7-1, KR 4555/9-1, KR 4555/10-1, and & WA 2673/15-1
Evidence before this study Anhedonia, a core symptom of depression, has traditionally been conceptualised as a deficit in consummatory pleasure. However, recent definitions have expanded to include anticipatory and motivational aspects of reward processing. Despite this evolution, experimental studies that systematically investigate these facets are lacking, with most animal models of anhedonia focusing on consummatory deficits.
Added value of this study This study contributes novel insights by demonstrating that patients with Major Depressive Disorder (MDD) and anhedonia exhibit reduced anticipatory wanting but not consummatory liking for food rewards. Bayesian hypothesis testing indicates strong evidence against the hypothesis of a consummatory deficit, suggesting instead a primary impairment in reward anticipation in anhedonia. Additionally, the study highlights the association between peripheral metabolic hormones and specific aspects of reward function, shedding light on the underlying mechanisms of anhedonia. Notably, lower insulin sensitivity and higher glucose levels were linked to symptoms of anhedonia, while elevated fasting acyl ghrelin levels were associated with increased food reward ratings.
Implications of all the available evidence The findings suggest that deficits in anticipatory wanting, rather than consummatory pleasure, may underlie anhedonia in MDD. This distinction has important implications for treatment strategies, as targeting incentive motivation and reward anticipation could be more effective in alleviating anhedonia symptoms. The observation that wanting improves with the proximity of the reward indicates a potential therapeutic approach focusing on enhancing reward proximity. Furthermore, the association between ghrelin and reward ratings suggests a role for gut-brain signalling in motivational symptoms, particularly in cases of depression involving loss of appetite and weight.
Competing Interest Statement
JK works as a study therapist in a multicenter phase IIb study by Beckley Psychtech Ltd on 5-MeO-DMT in patients with MDD, unrelated to this investigation. JK did not receive any financial compensation from the company. MW is a member of the following advisory boards and gave presentations to the following companies: Bayer AG, Germany; Boehringer Ingelheim, Germany; Novartis, Perception Neuroscience, HMNC and Biologische Heilmittel Heel GmbH, Germany. MW has further conducted studies with institutional research support from HEEL and Janssen Pharmaceutical Research for a clinical trial (IIT) on ketamine in patients with MDD, unrelated to this investigation. MW did not receive any financial compensation from the companies mentioned above. All other authors report no biomedical financial interests or other potential conflicts of interest.
Clinical Protocols
https://clinicaltrials.gov/study/NCT05318924
Funding Statement
The study was funded by DFG KR 4555/7-1, KR 4555/9-1, KR 4555/10-1, and & WA 2673/15-1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee/IRB of the University of Tuebingen, Faculty of Medicine, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 5 revised; author affiliations updated; Supplemental files updated, including additional analyses.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
